02252 Overview

Stock Performance: MEDBOT-B (02252.HK) saw a significant increase of 11.71%, with a short selling amount of $45.31 million and a ratio of 11.656%.

Product Orders: The company's core product, Toumai, has received over 200 orders, indicating a steady growth in demand, particularly in emerging markets like India and Brazil.

Market Expansion: MEDBOT-B has expanded its coverage to over 50 countries, with notable success in both emerging and developed markets, alleviating concerns about the sustainability of its growth.

Analyst Rating: JPMorgan has rated MEDBOT-B as Overweight, setting a target price of $41, highlighting its position as a leading domestic enterprise in China benefiting from import substitution trends.

JPMorgan's Forecast: JPMorgan's preliminary FY25 results for MEDBOT-B (02252.HK) exceeded market expectations but did not meet the broker's estimates.

Target Price Adjustment: The target price for MEDBOT-B has been reduced from HKD42 to HKD41, while maintaining an Overweight rating.

Market Position: MEDBOT-B is still considered JPMorgan's top pick in China's medical technology sector.

Short Selling Data: As of January 27, 2026, MEDBOT-B has a short selling amount of $12.08M and a ratio of 8.355%.

New Guidelines Released: China's National Healthcare Security Administration announced new guidelines for pricing pathological medical services, aiming to create a consistent pricing structure and promote a value-oriented reimbursement model.

Positive Market Impact: JPMorgan predicts these guidelines will positively affect the Chinese surgical robot market, enhancing visibility and commercialization for companies like MEDBOT-B.

MEDBOT-B Performance: Following the announcement, MEDBOT-B saw a 15% increase in stock price, reflecting investor confidence in the improved reimbursement mechanisms.

Analyst Rating: JPMorgan has assigned an Overweight rating to MEDBOT-B with a target price set at HKD42, indicating strong growth potential in the market.

Stock Performance: MEDBOT-B (02252.HK) opened up 5.3% and peaked at HKD32.56, last trading at HKD31.5 with a volume of 21.9397 million shares.

Financial Projections: The company anticipates a full-year revenue increase of approximately 1.1-1.2 times year-over-year, with an adjusted net loss expected to narrow by over 50% to no more than RMB240 million.

Market Performance: The HSI fell by 39 points (0.1%) to 26,447, while the HSTI rose by 8 points (0.1%) to 5,691, and the HSCEI decreased by 24 points (0.3%) to 9,070.

Active Heavyweights: Notable movements included XIAOMI down 2.3%, BABA up 1.1%, and TENCENT down 0.2%, with significant short selling activity across these stocks.

HSI & HSCEI Constituents: ANTA SPORTS and LI NING saw significant declines of 5.8% and 4%, respectively, while BIDU-SW increased by 3.3%, reaching a new high.

HSMI & HSSI Constituents: SKYWORTH surged by 37.6% to a new high, with TCL ELECTRONICS and SF INTRA-CITY also showing strong gains of 17.1% and 15.5%, respectively.

MEDBOT-B Stock Performance: MEDBOT-B (02252.HK) saw a significant increase of 30.377%, closing at $27.6 after peaking at $27.8, with trading volume reaching 17.6027 million shares.

Approval of UniPath: On December 24, MEDBOT-B announced that its UniPathTM Electronic Bronchoscopic Surgical Robotic System received official approval from China's National Medical Products Administration (NMPA).

A-Share Market Trends: Brain-computer interface stocks in the A-share market experienced notable gains, with XYME (688626.SH) rising 8.012% and other companies like MEHOW and INNOVATIVE MEDICAL also seeing increases.

Short Selling Activity: MEDBOT-B had a short selling volume of $47.45 million, with a short selling ratio of 10.439%, indicating significant market interest and activity.